SGAM
VRTX icon

Smith Group Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Smith Group Asset Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-55,746
Closed -$24.9M – 187
2026
Q1 		$24.9M Buy
55,746
+3,695
+7% +$1.72M 1.27% 35
2025
Q4 		$23.6M Buy
52,051
+3,194
+7% +$1.38M 1.25% 35
2025
Q3 		$19.1M Buy
48,857
+2,602
+6% +$1.09M 1.1% 37
2025
Q2 		$20.6M Buy
46,255
+612
+1% +$282K 1.35% 34
2025
Q1 		$22.1M Buy
45,643
+2,010
+5% +$937K 1.66% 31
2024
Q4 		$17.6M Sell
43,633
-26
-0.1% -$12.1K 1.3% 33
2024
Q3 		$20.3M Buy
43,659
+749
+2% +$360K 1.68% 30
2024
Q2 		$20.1M Buy
42,910
+1,872
+5% +$813K 1.78% 28
2024
Q1 		$17.2M Buy
41,038
+4,454
+12% +$1.88M 0.98% 37
2023
Q4 		$14.9M Buy
+36,584
New +$13.5M 0.87% 47
2022
Q1 		$4.97M Buy
+19,060
New +$4.52M 0.26% 80
2021
Q1 		– Sell
-29,220
Closed -$6.91M – 343
2020
Q4 		$6.91M Sell
29,220
-15,200
-34% -$3.49M 0.4% 54
2020
Q3 		$12.1M Sell
44,420
-110
-0.2% -$30.3K 0.63% 44
2020
Q2 		$12.9M Buy
+44,530
New +$12.1M 0.71% 41
2018
Q1 		– Sell
-65,010
Closed -$9.74M – 462
2017
Q4 		$9.74M Sell
65,010
-65,790
-50% -$9.74M 0.31% 76
2017
Q3 		$19.9M Sell
130,800
-60,280
-32% -$9.07M 0.66% 57
2017
Q2 		$24.6M Buy
+191,080
New +$23M 0.76% 55

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Smith Group Asset Management's VRTX Position: Q2 2026 in Review

Smith Group Asset Management sold out of Vertex Pharmaceuticals (VRTX) in Q2 2026, closing a stake of 55,746 shares — an estimated $24.9M sold.

Smith Group Asset Management first reported a position in VRTX in Q2 2017 and held it in 17 quarters. The position peaked at $24.9M in Q1 2026. 1,762 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Smith Group Asset Management reported no remaining Vertex Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Smith Group Asset Management sold 55,746 Vertex Pharmaceuticals shares in Q2 2026, an estimated $24.9M.
  • Smith Group Asset Management first reported a position in Vertex Pharmaceuticals in Q2 2017 and held it in 17 quarters.
  • Smith Group Asset Management's Vertex Pharmaceuticals position peaked at $24.9M in Q1 2026.
  • 1,762 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Smith Group Asset Management's 13F filing for Q2 2026, filed 3 Aug 2026.